Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 52

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 52
---
 facility for tab-cel. Based on the Board’s evaluation of the Company’s foregoing results and achievements in 2024 and in particular, considering the receipt of a Complete Response Letter for the tab-cel BLA and clinical holds on our active INDs, and as recommended by the Human Capital Committee, the Board approved a 50% achievement of the 2024 corporate goals.

<div align='center'>33</div>

In consideration of the foregoing, in February 2025, pursuant to the terms and conditions of the applicable annual bonus guidelines, the Human Capital Committee approved annual cash bonus payments for each named executive officer as reflected in the table below.

| Name                   |     | 2024 Bonus 
 Target     |         |     | Corporate Score Modifier |    |   |     | 2024 Actual          
 Bonus to be Paid (1) |         |     |    |
|:-----------------------|:----|:-----------|--------:|:----|:-------------------------|---:|:--|:----|:---------------------|--------:|:----|---:|
| AnhCo Nguyen, Ph.D.    |     | $          | 291,616 |     |                          | 50 | % |     | $                    | 145,808 |     | -2 |
| Eric Hyllengren        |     | $          | 234,000 |     |                          | 50 | % |     | $                    | 117,000 |     | -2 |
| Jill Henrich           |     | $          | 225,000 |     |                          | 50 | % |     | $                    |       — |     | -3 |
| Pascal Touchon, D.V.M. |     | $          | 470,243 |     |                          | 50 | % |     | $                    |       — |     | -3 |
| Amar Murugan           |     | $          | 231,750 |     |                          | 50 | % |     | $                    |       — |     | -3 |

(1) The Company expects to pay the 2024 annual bonuses to eligible employees in the second quarter of 2025. (2) As noted below in the 2024 Summary Compensation Table, in addition to the above-mentioned bonus payment, in consideration of their significant efforts towards the successful acceptance of our biologics license application (BLA) for tab-cel by the United States Food and Drug Administration